证券代码：600055 证券简称：万东医疗 编号：临 2024-001 北京万东医疗科技股份有限公司 关于取得医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 北京万东医疗科技股份有限公司（以下简称"公司"）于近日收 到国家药品监督管理局颁发的《中华人民共和国医疗器械注册证》， 具体情况如下： 一、 医疗器械注册证的具体情况 注册证编号：国械注准20233062023 注册人名称：北京万东医疗科技股份有限公司 注册人住所：北京市朝阳区酒仙桥东路9号院3号楼 生产地址：北京市朝阳区酒仙桥东路9号院3号楼 产品名称：X射线计算机体层摄影设备 型号、规格：TurboTom 5、TurboTom 5 PLUS 批准日期：二〇二三年十二月二十五日 生效日期：二〇二三年十二月二十五日 有效期至：二〇二八年十二月二十四日 二、 同类产品相关情况 根据国家药品监督管理局官网数据查询信息，截至公告日，国内 外同行业相关厂家已取得同类医疗器械注册证书。 三、 对公司业绩的影响 本注册证为公司64排128层CT产品系列的第二张 ...

证券代码：600055 证券简称：万东医疗 编号：临 2023-028 北京万东医疗科技股份有限公司 关于取得医疗器械注册证的公告 注册证编号：国械注准20233061998 注册人名称：北京万东医疗科技股份有限公司 型号、规格：TurboTom 5 S、TurboTom 5 S PLUS 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 北京万东医疗科技股份有限公司（以下简称"公司"）于近日收 到国家药品监督管理局颁发的《中华人民共和国医疗器械注册证》， 具体情况如下： 一、 医疗器械注册证的具体情况 生产地址：北京市朝阳区酒仙桥东路9号院3号楼 产品名称：X射线计算机体层摄影设备 结构及组成：由高压发生器、医用诊断X射线管组件、限束器、扫 描架、患者支架、探测器、CT控制台（含CT控制盒、控制台计算机、 显示器）、图像处理系统、电源分配柜、摄像头和附件组成。附件包 括头托、延长板、头垫、床垫、脚闸组成，具体见产品技术要求。 批准日期：二〇二三年十二月二十二日 注册人住所：北京市朝阳区酒仙桥东路9号院3号楼 上述64排128 ...

北京万东医疗科技股份有限公司独立董事 关于聘任公司总裁事项的独立意见 根据《公司法》、《上市公司独立董事管理办法》、《上市公司治理准则》 和《公司章程》等相关规章制度的有关规定，作为北京万东医疗科技股份 有限公司（以下简称"公司"）独立董事，我们对公司第九届董事会第十 三次会议作出的关于公司聘任总裁事项发表如下意见： 同意聘任宋金松先生担任总裁职务。本次聘任符合《公司法》、《上海 证券交易所股票上市规则》及《公司章程》等法律法规、规范性文件规定 的任职条件，被聘任人具备担任公司高级管理人员的资格和能力。本次公 司总裁的提名、聘任程序符合有关法律法规、规范性文件之规定，不存在 被中国证监会确定为市场禁入者并尚未解除的情形。不存在损害公司及全 体股东尤其是中小股东利益的情形。 北京万东医疗科技股份有限公司 2023 年 12 月 8 日 (本页无正文, 为《北京万东医疗科技股份有限公司独立董事对聘任公司 总裁事项的独立意见》的签字页 ) 独立董事签字: 潘飞 独立董事 李红霞 独立董事 邹卓 独立董事 ...

证券代码：600055 证券简称：万东医疗 编号：临 2023-027 董事会提名委员会对总裁人选及其任职资格审核通过，公司第九届 董事会第十三次会议审议并通过《关于聘任公司总裁的议案》，同意聘 任宋金松先生为公司总裁（简历附后），任期自本次会议审议通过之日 起至本届董事会任期届满日止。 独立董事对本次聘任总裁事项发表了同意的独立意见，详见同日披 露于上海证券交易所网站的《万东医疗独立董事关于聘任公司总裁事项 的独立意见》。 截至本公告披露日，宋金松先生未持有公司股票，与公司的董事、 监事、高级管理人员、实际控制人及持股5%以上的股东不存在关联关系。 任职资格符合《公司法》及《公司章程》的相关规定，不存在《上海证 券交易所上市公司自律监管指引第1号——规范运作》第3.2.2条所列情 形。 特此公告。 北京万东医疗科技股份有限公司 关于董事、总裁辞职暨聘任总裁的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法 律责任。 北京万东医疗科技股份有限公司（以下简称"公司"）董事会于近 日收到公司董事、总裁谢宇峰先生的书面辞职报告，谢宇峰先 ...

证券代码：600055 证券简称：万东医疗 公告编号：临 2023-025 北京万东医疗科技股份有限公司关于 召开 2023 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： （一）会议召开时间：2023 年 11 月 17 日下午 16:00-17:00 （二）会议召开地点：上证路演中心 （三）会议召开方式：上证路演中心网络互动 会议召开时间：2023 年 11 月 17 日(星期五)下午 16:00-17:00 会 议 召 开 地 点 ： 上海证券 交易所上证路演中心（ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 11 月 10 日(星期五)至 11 月 16 日(星期四)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 wdm_ir@wandong.com.cn 进行提问。公司将在说明会上对投资者普遍关注的 问题进行回答。 北京万东医疗科技股份有限公司（以下简称" ...

证券代码：600055 证券简称：万东医疗 编号：临 2023-026 北京万东医疗科技股份有限公司 关于对外投资设立全资子公司的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责 任。 重要内容提示： 投资标的名称：苏州万影医疗科技有限公司 一、对外投资概况 1、对外投资的基本情况 根据公司战略发展布局的需要，充分利用地方政策及产业配套资源优 势，公司以自有资金 10,000 万元在苏州投资设立全资子公司苏州万影医疗 科技有限公司。 2、对外投资的决策与审批情况 根据《上海证券交易所股票上市规则》、《北京万东医疗科技股份有 限公司章程》等规定，本次对外投资事项已经经理办公会审批并报董事长 批准，无需提交董事会或股东大会审议。 3、本次对外投资不构成关联交易以及《上市公司重大资产重组管理办 法》规定的重大资产重组。 二、投资设立全资子公司基本情况 投资金额：人民币10,000万元 特别风险提示：本次投资设立全资子公司可能面临宏观政策调控、 市场变化、经营管理等方面的不确定因素。请广大投资者理性投资，注意 投资风险。 公司名称：苏 ...

Financial Performance - The company's operating revenue for Q3 2023 reached ¥331,458,962.91, representing a year-on-year increase of 20.04%[4] - Net profit attributable to shareholders for the same period was ¥44,142,718.87, with a slight increase of 0.75% compared to the previous year[4] - The net profit after deducting non-recurring gains and losses was ¥34,789,971.16, showing a decrease of 13.29% year-on-year[4] - Year-to-date revenue until the end of the reporting period was ¥925,789,900.33, reflecting a growth of 26.36% compared to the same period last year[4] - Year-to-date net profit attributable to shareholders reached ¥120,183,411.96, an increase of 16.54% year-on-year[4] - The basic earnings per share for Q3 2023 was ¥0.063, down by 7.35% compared to the same period last year[4] - The weighted average return on equity for the reporting period was 0.95%, a decrease of 0.20 percentage points year-on-year[4] - Net profit for the first three quarters of 2023 was ¥121,823,300.98, representing a 17.9% increase from ¥103,293,470.00 in the same period of 2022[14] - The comprehensive income attributable to the parent company for the third quarter of 2023 was approximately $120.18 million, compared to $103.13 million in the same quarter of 2022, representing an increase of about 16.5%[30] - Basic and diluted earnings per share for the third quarter of 2023 were both reported at 0.171 yuan, an increase from 0.160 yuan in the same quarter of 2022, reflecting a growth of about 6.9%[30] Cash Flow and Assets - The net cash flow from operating activities for the year-to-date period was ¥46,814,270.40, which represents a decline of 35.64% compared to the previous year[4] - The net cash flow from operating activities was CNY 46,814,270.40, a decrease of 35.64% compared to the previous year[16] - Cash inflow from investment activities totaled CNY 850,587,310.47, down from CNY 939,485,815.23 in the previous year[16] - The net cash flow from investment activities was CNY -413,747,838.88, an improvement from CNY -554,508,445.81 in the previous year[16] - Cash inflow from financing activities was CNY 2,000,000.00, significantly lower than CNY 2,101,222,961.50 in the previous year[16] - The net cash flow from financing activities decreased by 104.19% to CNY -85,189,830.68 compared to the previous year[16] - As of September 30, 2023, the company's cash and cash equivalents decreased to approximately $2.80 billion from $3.24 billion as of December 31, 2022, representing a decline of about 13.6%[27] - The total current assets amounted to approximately $4.23 billion, slightly down from $4.27 billion at the end of 2022, indicating a decrease of about 1.0%[27] - The company's total assets increased to approximately $5.28 billion as of September 30, 2023, compared to $5.26 billion at the end of 2022, reflecting a growth of about 0.1%[38] - The company's total liabilities amounted to ¥519,532,140.61, a decrease from ¥551,981,473.99 in the previous reporting period[13] - The total equity attributable to shareholders reached ¥4,647,866,254.95, up from ¥4,605,403,996.79 in the previous period[13] - The total current liabilities decreased to approximately $466.14 million from $492.08 million at the end of 2022, indicating a decline of about 5.3%[38] Research and Development - Research and development expenses increased to ¥109,772,089.94 in 2023, compared to ¥83,910,445.95 in 2022, reflecting a growth of 30.9%[14] - The company increased its R&D expenses by 30.82%, reflecting a commitment to enhancing innovation[22] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 31,568[9] - Major shareholder Midea Group holds 45.46% of the shares, totaling 319,579,981 shares[10] Income and Liabilities - The company reported a financial income of ¥50,907,958.00, an increase from ¥32,959,936.23 in the same period last year[14] - The company’s deferred income tax liabilities were recorded at ¥349,301.01, down from ¥396,616.35 in the previous period[13] - The company's inventory increased to approximately $341.43 million as of September 30, 2023, compared to $266.62 million at the end of 2022, indicating a rise of about 28.0%[27] - Long-term receivables rose to approximately $195.33 million from $114.53 million year-over-year, showing an increase of about 70.6%[27] - The company's total non-current assets reached approximately $1.05 billion, up from $996.26 million at the end of 2022, reflecting an increase of about 5.5%[38] Government Subsidies and Investment Income - The company received government subsidies amounting to CNY 7,874,311.47, which contributed to an increase in other income by 60.52%[20] - The company reported a decrease in investment income by 63.30% due to the expiration of previously invested financial products[22]

北京万东医疗科技股份有限公司关于 使用闲置募集资金进行现金管理的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法 律责任。 重要内容提示： 产品种类：银行理财 本次现金管理总额：1 亿元 履行的审议程序：2023 年4 月17 日召开的第九届董事会第九次会议、 第九届监事会第九次会议及 2023 年 5 月 12 日召开的 2022 年年度股东大会 审议批准《关于使用部分暂时闲置募集资金进行现金管理的议案》。 一、情况概述 （一）现金管理目的 北京万东医疗科技股份有限公司（以下简称"公司"）为提高募集资 金效率，合理利用部分闲置募集资金，在确保不影响募集资金项目建设和 使用、募集资金安全的情况下，增加公司的收益，为公司及股东获取更多 回报。 证券代码：600055 证券简称：万东医疗 编号：临 2023-024 | 受托方名称 | 产品 | 产品名称 | 金额 | 预计年化 | | --- | --- | --- | --- | --- | | | 类型 | | （万元） | 收益率 | | 招商银行股份有限公司 | 银行 ...

一、情况概述 （一）现金管理目的 证券代码：600055 证券简称：万东医疗 编号：临 2023-023 北京万东医疗科技股份有限公司关于 使用闲置募集资金进行现金管理的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法 律责任。 重要内容提示： 产品种类：银行理财 本次现金管理总额：1.3 亿元 履行的审议程序：2023 年4 月17 日召开的第九届董事会第九次会议、 第九届监事会第九次会议及 2023 年 5 月 12 日召开的 2022 年年度股东大会 审议批准《关于使用部分暂时闲置募集资金进行现金管理的议案》。 北京万东医疗科技股份有限公司（以下简称"公司"）为提高募集资 金效率，合理利用部分闲置募集资金，在确保不影响募集资金项目建设和 使用、募集资金安全的情况下，增加公司的收益，为公司及股东获取更多 回报。 （二）现金管理金额 本次现金管理总金额为 1.3 亿元。 （三）资金来源及相关情况 本次现金管理的资金来源为闲置募集资金。 经中国证券监督管理委员会《关于核准北京万东医疗科技股份有限公 司非公开发行股票的批复》 ...

Financial Performance - The company's operating revenue for the first half of 2023 reached ¥594,330,937.42, representing a 30.19% increase compared to ¥456,521,773.90 in the same period last year[4]. - The net profit attributable to shareholders for the same period was ¥76,040,693.09, up 28.21% from ¥59,311,322.24 year-on-year[4]. - The basic earnings per share for the first half of 2023 was ¥0.108, a 12.50% increase from ¥0.096 in the same period last year[4]. - The total comprehensive income for the period was CNY 77,642,229.10, compared to CNY 59,559,461.94 in the previous year, marking a 30.3% increase[169]. - The total profit for the period was CNY 93,986,034.32, compared to CNY 70,980,527.32 in the previous year, indicating a growth of 32.4%[169]. Cash Flow and Assets - The net cash flow from operating activities was ¥23,207,023.89, reflecting an 11.15% increase from ¥20,878,247.01 in the previous year[4]. - The company's cash and cash equivalents decreased by 16.07% to CNY 2,720,600,620.54, compared to CNY 3,241,421,962.85 at the end of the previous year[35]. - The cash inflow from operating activities for the first half of 2023 was approximately ¥781.12 million, an increase of 33.2% compared to ¥586.01 million in the same period of 2022[165]. - The total assets at the end of the reporting period were ¥5,262,961,528.92, showing a slight increase of 0.01% compared to ¥5,262,599,175.73 at the end of the previous year[4]. - The total liabilities decreased to CNY 2,769,663,206.47, indicating improved financial health[195]. Research and Development - Research and development expenses increased by 30.86% to CNY 64,569,201.91, reflecting the company's commitment to enhancing R&D investment[33]. - The company is actively developing AI projects related to imaging equipment to meet clinical needs and enhance technological capabilities[29]. - Research and development expenses rose to approximately $56.56 million, up from $35.59 million, indicating a significant increase of 58.9%[156]. Market and Product Development - The company specializes in the research, production, and sales of large medical imaging equipment, including DR, MRI, CT, DSA, and DM systems[20]. - Sales of CT products saw a significant increase of nearly 200% year-on-year, becoming the main driver of revenue growth during the reporting period[28]. - The company launched new products including the 32-slice CT and 50kW mobile DR, enhancing its product lines in CT and DR[24]. - The company plans to expand its market presence and invest in new product development to drive future growth[200]. Related Party Transactions - The company reported a total of 58,511,278.84 in related party transactions, accounting for 11.34% of similar transaction amounts[69]. - The company has committed to maintaining independence in assets, personnel, finance, business, and institutions with respect to Wandong Medical[66]. - The company will minimize related party transactions and ensure fairness in pricing according to market principles[68]. Financial Health and Stability - The company confirmed that there were no major risks that could significantly impact its operations during the reporting period[92]. - The financial statements were prepared in accordance with the relevant accounting standards and accurately reflect the company's financial status[99]. - The company has not engaged in any non-operational fund occupation by controlling shareholders or related parties[92]. Future Outlook - Future guidance indicates a cautious but optimistic outlook for revenue growth in the upcoming quarters[200]. - The company is focusing on enhancing its technology capabilities to improve operational efficiency and customer satisfaction[200].